Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery - sprookjes - yvandenbroek - TriplyDB

Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery

Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery

http://www.wikidata.org/entity/Q34729209

about

Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor.CINPA1 is an inhibitor of constitutive androstane receptor that does not activate pregnane X receptor.Transactivation and Coactivator Recruitment Assays for Measuring Farnesoid X Receptor Activity.Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor Characterizing ligands for farnesoid X receptor--available in vitro test systems for farnesoid X receptor modulator development.Differential modulation of FXR activity by chlorophacinone and ivermectin analogs.Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4

P2860

Q34101208-81564057-FE62-48A1-8C5F-C42B7889C47A Q35531860-F428C13E-89F6-49F1-B166-C634D12DBE97 Q36102862-FE435D5B-05CE-4C04-A8B3-7173D8038C52 Q36972583-D3DEBC7A-1BE4-4D3F-BE7D-65B8078B2C4D Q38164798-A98C01C3-7CD6-47C0-88D1-B320950BEE21 Q50038475-5C60EA57-B0DB-4089-A5DC-67366F12A208 Q57810693-0332C7ED-4437-40FE-8246-8E40A92A5FDC

P2860

Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery

http://www.wikidata.org/entity/Q34729209

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Development of time resolved f ...... y for FXR antagonist discovery

@ast

Development of time resolved f ...... y for FXR antagonist discovery

@en

Development of time resolved f ...... y for FXR antagonist discovery

@nl

type

label

Development of time resolved f ...... y for FXR antagonist discovery

@ast

Development of time resolved f ...... y for FXR antagonist discovery

@en

Development of time resolved f ...... y for FXR antagonist discovery

@nl

prefLabel

Development of time resolved f ...... y for FXR antagonist discovery

@ast

Development of time resolved f ...... y for FXR antagonist discovery

@en

Development of time resolved f ...... y for FXR antagonist discovery

@nl

P1433

Q34729209-A240FFE3-559C-48CC-87B5-4A82D908F737

P1476

Q34729209-36722EF0-CC1A-4FC6-9A0D-059C1D4E3667

P2093

Q34729209-3DA858A5-067A-4844-B210-CD3DE7E403B4

Q34729209-63AE66F4-7D37-47A6-A04F-E51F4082ABA9

Q34729209-BE3CAA4B-D581-4E9A-A24A-A51E4DEE80B8

Q34729209-C4DB12A4-0283-4690-83B1-C8FD31BBCA8F

P2860

Q34729209-0501AB4C-0771-4589-A183-F85DD2D319BD

Q34729209-07A1EED8-BC86-443F-B9F2-BB37EAA2F936

Q34729209-0E938BA2-CB60-4285-8407-FA432DE96C0A

Q34729209-158FDE22-2729-46DD-8C90-4FD39B4F2C1D

Q34729209-3276F3AF-72BA-4DB1-A7BD-3D7AC0BAF276

Q34729209-357899D1-4A60-4F73-ABAE-F3EB06C87B87

Q34729209-3AC2FF95-2CF3-4B5B-A7C3-EE6D9BE1EAB5

Q34729209-3ACFBF8A-FBAF-4033-BB14-B09E359FCF26

Q34729209-4BEACD18-E890-4B15-8C83-00249440E1AC

Q34729209-645D1396-A7FB-4D4D-908F-EBD54FE27334

P304

Q34729209-80D885A7-5342-4632-A960-C324C0299968

P31

Q34729209-361927D3-8072-4967-A22C-6C2DBD464EE6

P356

Q34729209-86BCA9DE-7A57-4165-94C4-F09FEA3F7D21

P407

Q34729209-B339B3B0-031B-4863-9957-A26D5670AFF5

P433

Q34729209-EFFDBDFB-76B5-43CD-9E74-EF1F275C9357

P478

Q34729209-9BE0433F-F016-47CD-B6CB-A7ADBEAD9C73

P577

Q34729209-240150CD-CDAF-4BB2-8E5F-6619045DED39

P698

Q34729209-7C27E814-26ED-420C-BC76-E7247E204235

P932

Q34729209-D63AE237-4C9D-40D5-850E-D664286F70AA

P356

J.BMC.2013.04.069

P1433

Bioorganic & Medicinal Chemistry

P1476

Development of time resolved f ...... y for FXR antagonist discovery

@en

P2093

Barry M Forman

http://www.w3.org/2001/XMLSchema#string

Donna D Yu

http://www.w3.org/2001/XMLSchema#string

Taosheng Chen

http://www.w3.org/2001/XMLSchema#string

Wenwei Lin

http://www.w3.org/2001/XMLSchema#string

P2860

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity

Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis

Structural basis for bile acid binding and activation of the nuclear receptor FXR

Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064

Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064

Modulation of Pantothenate Kinase 3 Activity by Small Molecules that Interact with the Substrate/Allosteric Regulatory Domain

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR

Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders

P304

4266-4278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BMC.2013.04.069

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23688559

http://www.w3.org/2001/XMLSchema#string

P932

3691817

http://www.w3.org/2001/XMLSchema#string